Despite drawbacks and deceptions, which are connatural to the implementation of any new therapy, regenerative cardiology offers a promising therapeutic potential. BMC and MSC are the cells most often used in human trials. The first ones have the advantage that biosecurity has been extensively tested. Recent research has suggested that plasticity of MSC may be larger, but tests on long-term security are pending. Stromal BMC are at the intersection of these two cell types. Clinical assays with BMC have shown only modest therapeutic results. It is time, perhaps, to revise the protocols and designs to look for the improvement of results. Getting insight into the mechanisms would be most important to guide rational modifications of the design, and this may require more basic and clinical research Recently discovered CSC add new excitement and expectancies. Drugs able to awake CSC, mobilize them and generate myocytes in situ or expansion of CSC in vitro followed by re-injection at the damaged spot are two of the most obvious expectative goals. It must be remembered that at least some cardiac progenitor pools can be refilled by circulating BMC. ESC will need more time to enter into therapeutics, but this does not mean they are less important as an object of investigation. On the contrary, the study of proliferation and differentiation of ESC should inspire regenerative medicine. We must assimilate and transmit the idea that research on different types of stem cells is not antithetical, but complementary.